Significant breakthrough in search for Parkinson's biomarker (michaeljfox.org)

Article summary

The Michael J. Fox Foundation has announced a significant breakthrough in the search for a Parkinson's biomarker, with the development of a test that can detect alpha-synuclein pathology in spinal fluid with high sensitivity and specificity. This test, known as the alpha-synuclein seed amplification assay (αSyn-SAA), has the potential to revolutionize the diagnosis and treatment of Parkinson's disease. The test has been validated in a large-scale study and is now available for diagnostic assessment. The discovery of this biomarker is expected to accelerate the development of new treatments and improve clinical trial design.

Main themes

• Parkinson's biomarker
• Alpha-synuclein seed amplification assay
• Diagnosis and treatment
• Clinical trials
• Pharmaceutical industry
• Supplements and alternative treatments
• Environmental toxins and genetic factors

What commenters say

• The discovery of a Parkinson's biomarker is a significant breakthrough that could lead to earlier diagnosis and treatment of the disease.
• The new test may not be a game-changer for diagnosis, as Parkinson's can already be diagnosed through other means, but it could be useful for clinical trials and understanding the disease biology.
• The lack of a patentable drug may limit the interest of pharmaceutical companies in developing treatments for Parkinson's, despite the potential benefits of certain supplements like thiamine.
• Some commenters are skeptical about the significance of the breakthrough, citing the need for more research and the potential for false positives or misdiagnosis.
• The development of a biomarker could lead to more targeted and effective treatments, and potentially even prevention of the disease.
• There is a need for more research into the causes and mechanisms of Parkinson's, including the potential role of environmental toxins and genetic factors.
• The use of steroids in treating certain medical conditions, including COVID-19, is a complex issue that requires careful consideration of the potential benefits and risks.
• Some alternative treatments, such as thiamine supplementation, may have potential benefits for Parkinson's patients, but more research is needed to fully understand their effects.